

Strategy for Brain Cancer Stem Cell sorting with SdFFF.

Routine BTSC sub-populations preparation for biosensor calibration.



G. Bégaud¹, B. Bessette¹, S. Saada¹, R. Manczak², M. Mancuso³, F. Lalloué¹, C. Dalmay², A. Pothier², P.J.P. Cardot¹, S. Battu¹

Aim of the study Background: Glioblastoma and medulloblastoma are one of the most aggressive brain tumors. Such as several types of solids tumors, their high tumorogenicity is based on their high heterogeneity and the presence of Brain Tumor Stem cells (BTSC) which explains tumor growth, spreading and the number of relapses after treatment. Therefore, BTSC characterization and isolation are of high importance in cancer studies. As major difficulties reside in the isolation (low amounts in tumors < 1-2 %) and in the characterization (lack of specific markers) of these potential biological targets, new technology development without immuno-labelling could be of great interest. In that way, our labs works since 10 years in the development of specific non-invasive microwave biosensors able to detect and characterized BTCS (BioCapteur and CCRMES projects). In the frame of the SUMCASTEC project (Semiconductor-based Ultrawideband Micromanipulation of CAncer STEm Cells, Horizon 2020 Framework Programme FET OPEN, N° 737164) we developed a novel non-invasive microoptofluidic lab-on-chip (LOC) platform able to deliver ultra-wide broadband radiation to compare cell spectral signatures, image subcellular features, and hence modulate BCSCs microenvironment in order to differentiate it, and then reduced their aggressiveness. Goal: in order to properly calibrate the biosensor response regarding to the BTCS properties (specificity, sensitivity...), we need to produce purified and calibrated population of BTSC, in that way, we purpose to use Sedimentation Field Flow Fractionation, a non-invasive and labelfree method to sort BTSC of various degrees of differentiation.

Glioblastoma


- Primary brain tumor: 2% of all cancer and 70% of brain tumors.
- Grade IV astrocytoma (WHO).
- Dark vital pronostic: relative percentage of survey 30% after 1Y and only 9.8 % after 5Y
- Total surgical resection is very difficult (invasive tumor).
- Important pool of quiescent Brain Tumor Stem Cells (BTSC) which resist to chemo- and radiotherapy.
- Specific micro-environment with important neo-vascularisation, exosomes and miR secretion by BTSC controlling tumorogenesis, neo-vascuarisation and tissue infiltration




BTSC:


- Purification (SdFFF)
- Identification
- Detection (BioCapteur project)
- Characterization (biological analysis)

is our first interest in order to develop specific therapies or to induce selective differentiation into chemo- and radiotherapy sensitive cells = SUMCASTEC project.



Cell sorting methods could be classify by their application scale (macro and micro- or nano methods) or by the principle of sorting such as the use of immunological recognition (FACS, MACS), or intrinsic biophysical properties of cells. Among these last methods, we developed since 15 years, prototypes and applications for sedimentation field flow fractionation (SdFFF), a non-invasive macro-method based on cell size, density, rigidity, respecting cell viability, functionality and differentiation state, SdFFF have been successfully used to sort. without any labeling, normal and cancer stem cells (CSC) from different glioblastoms uroblastoma or colorectal cancer cell lines.





Conclusion: Association of cultural conditions and SdFFF cell sorting allowed to prepare enriched population with different BTSC contents. All the sorted fractions present specific stemness properties ranging from differentiated to very undifferentiated sub-populations. In each the cases, whatever the technologies on which the sensor are based, we obtained very specific responses, demonstrated a good correlation between biological state/BTSC content and sensor response. Then it was possible to routinely prepare BTSC populations in order to calibrate sensors, which will be further used, in particular for the SUMCASTEC project, for clinical application to detect and modify BTSC into more therapies sensitive population.



This project has received funding from the European Union's Horizon 2020 Framework Programme Sumcastec FET OPEN Research and innovation under grant agreement N° 737164

